Zobrazeno 1 - 10 of 18 pro vyhledávání: '"Jagdev S. Sidhu"'
1
Exposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema
Autor: Timothy J. Craig, Jagdev S. Sidhu, Ingo Pragst, Dipti Pawaskar, Michael A. Tortorici, Bruce L. Zuraw, Marco Cicardi, Thomas Machnig, Matthew Hutmacher, Hilary Longhurst, Ying Zhang
Publikováno v: CPT: Pharmacometrics & Systems Pharmacology. 7:158-165
Subcutaneous C1-inhibitor (HAEGARDA, CSL Behring), is a US Food and Drug Administration (FDA)-approved, highly concentrated formulation of a plasma-derived C1-esterase inhibitor (C1-INH), which, in the phase III Clinical Studies for Optimal Managemen
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::86426a31235f989ee445e82d6469dabf
https://doi.org/10.1002/psp4.12271
Zobrazit plný text záznamu
2
Population pharmacokinetics of recombinant coagulation factor VIII‐SingleChain in patients with severe hemophilia A
Autor: Alex Veldman, Ying Zhang, John Roberts, Jagdev S. Sidhu, Michael A. Tortorici, Annette Feussner, K. St. Ledger
Publikováno v: Journal of Thrombosis and Haemostasis. 15:1106-1114
Essentials rVIII-SingleChain is a unique recombinant factor VIII (FVIII) molecule. A population pharmacokinetic model was based on FVIII activity of severe hemophilia A patients. The model was used to simulate factor VIII activity–time profiles for
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e879b042cead9d475b97bef9120084ce
https://doi.org/10.1111/jth.13662
Zobrazit plný text záznamu
4
Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema
Autor: H. Henry Li, Paul K. Keith, Michael A. Tortorici, Bruce L. Zuraw, Inmaculada Martinez-Saguer, Hilary Longhurst, Jagdev S. Sidhu, Timothy J. Craig, Constance H. Katelaris, Jonathan A. Bernstein, Joshua J. Jacobs, Marc A. Riedl, William R. Lumry, Marco Cicardi, Annette Feussner, Dipti Pawaskar
Publikováno v: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 48(10)
Background Long-term prophylaxis with subcutaneous (SC) administration of a highly concentrated plasma-derived C1-esterase inhibitor (C1-INH) formulation was recently approved by the Food and Drug Administration for hereditary angioedema (HAE) attack
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a99aaedf35d99184b5748c5a5d45b1be
https://pubmed.ncbi.nlm.nih.gov/29998524
Zobrazit plný text záznamu
5
Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate
Autor: Jonathan A. Bernstein, Inmaculada Martinez-Saguer, Hilary Longhurst, Henrike Feuersenger, R. Parasrampuria, Huamin Henry Li, Marco Cicardi, Bruce L. Zuraw, Jonathan M. Edelman, Timothy J. Craig, Petra Staubach, Syed M. Rehman, Markus Magerl, Jagdev S. Sidhu
Publikováno v: Allergy
Background Hereditary angioedema (HAE) due to C1 inhibitor deficiency manifests as recurrent swelling attacks that can be disabling and sometimes fatal. Long‐term prophylaxis with twice‐weekly intravenous injections of plasma‐derived C1‐inhib
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29918b082a6aa1b0a9a2f6c80659ff18
https://doi.org/10.1111/all.12658
Zobrazit plný text záznamu
6
Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency
Autor: Mikhail Rojavin, Jonathan M. Edelman, Jagdev S. Sidhu, Marc Pfister
Publikováno v: Biologics in Therapy
Introduction Standard treatment for patients with primary immunodeficiency (PID) is monthly intravenous immunoglobulin (IVIG), or weekly/biweekly subcutaneous immunoglobulin (SCIG) infusion. We used population pharmacokinetic modeling to predict immu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1011b7c8b3b3272aaa9c3acb50ab82a
http://europepmc.org/articles/PMC4254869
Zobrazit plný text záznamu
7
Pharmacokinetic Modeling and Simulation of Biweekly Subcutaneous Immunoglobulin Dosing in Primary Immunodeficiency
Autor: Carl M. J. Kirkpatrick, Martin Bexon, Jianfeng Lu, Mikhail Rojavin, Jonathan M. Edelman, Cornelia B. Landersdorfer, Jagdev S. Sidhu, Mark Pfister
Publikováno v: Postgraduate Medicine. 125:53-61
Replacement therapy with immunoglobulin G (IgG) given as intravenous or subcutaneous (SC) infusions is the standard treatment for patients with primary immunodeficiency. Due to the life-long need for replacement, increased flexibility in the administ
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29bb824253baae56edefc09f5f0be94d
https://doi.org/10.3810/pgm.2013.11.2712
Zobrazit plný text záznamu
8
Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B
Autor: John Roberts, Elena Santagostino, Christine Voigt, Massimo Morfini, Debra M. Bensen-Kennedy, Ying Zhang, Jagdev S. Sidhu, Annette Feussner, Iris Jacobs
Publikováno v: Journal of thrombosis and haemostasis : JTH. 14(11)
Essentials The new recombinant factor IX (FIX) albumin fusion protein (rIX-FP) has a prolonged half-life. A population pharmacokinetic (PK) model was based on FIX activity levels of hemophilia B patients. The model was used to simulate different dosi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58b735fe7cdd7bc9ba3c21e69e829fa9
https://pubmed.ncbi.nlm.nih.gov/27513989
Zobrazit plný text záznamu
9
Subcutaneous immunoglobulin loading regimens for previously untreated patients with primary antibody deficiency
Autor: Marc Pfister, Mikhail Rojavin, Alphonse Hubsch, Jagdev S. Sidhu
Publikováno v: Clinical & Experimental Immunology. 178:146-148
Immunoglobulin (Ig)G therapy is the primary treatment for patients with primary antibody deficiencies (PAD), and can be administered intravenously [intravenous immunoglobulin (IVIg)] or subcutaneously [subcutaneous immunoglobulin (SCIg)]. IVIg has be
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bc10292168bd31bb6f9b2b9dedaaebad
https://doi.org/10.1111/cei.12548
Zobrazit plný text záznamu
10
Single-Dose, Comparative Study of Venous, Capillary and Salivary Artemisinin Concentrations in Healthy, Male Adults
Autor: Michael Ashton, Jagdev S. Sidhu
Publikováno v: The American Journal of Tropical Medicine and Hygiene. 56:13-16
A comparison of venous plasma, capillary plasma, and saliva pharmacokinetics of artemisinin was performed in four healthy subjects given a single 500 mg dose. Artemisinin was determined to be 88% bound in venous plasma. Saliva levels were more closel
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83a3935b50fb7425f92f2db69a3bb6e5
https://doi.org/10.4269/ajtmh.1997.56.13
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje